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Alzheimer’s disease (AD) is characterized by deﬁcits in cerebral metabolic rates of glucose in the pos-
terior cingulate (PC) and precuneus in AD subjects, and in APOEε4 carriers, decades before the onset of
measureable cognitive deﬁcits. However, the cellular and molecular basis of this phenotype remains to
be clariﬁed. Given the roles of astrocytes in energy storage and brain immunity, we sought to charac-
terize the transcriptome of AD PC astrocytes. Cells were laser capture microdissected from AD (n ¼ 10)
and healthy elderly control (n ¼ 10) subjects for RNA sequencing. We generated >5.22 billion reads and
compared sequencing data between controls and AD patients. We identiﬁed differentially expressed
mitochondria-related genes including TRMT61B, FASTKD2, and NDUFA4L2, and using pathway and
weighted gene coexpression analyses, we identiﬁed differentially expressed immune response genes.
A number of these genes, including CLU, C3, and CD74, have been implicated in beta amyloid generation
or clearance. These data provide key insights into astrocyte-speciﬁc contributions to AD, and we present
this data set as a publicly available resource.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
With the rapidly growing prevalence of Alzheimer’s disease
(AD), improved understanding of themolecular and cellular basis of
the disease is needed to identify and develop improved diagnostics
and treatments. Numerous imaging studies have set the stage for
characterizing AD in live subjects. Using ﬂuorodeoxyglucose posi-
tion emission tomography (FDG-PET), researchers have character-
ized an association between AD and progressive reductions of
cerebral metabolic rates of glucose (CMRgI) in both AD patients
(Minoshima et al., 1997; Reiman et al., 1996, 2001, 2004) and young
adult APOEε4 carriers 4 decades before the expected onset ofion, Translational Genomics
5004, USA. Tel.: þ1 602 343
Inc. This is an open access article ucognitive deﬁcits (Reiman et al., 2004). Affected brain regions
include the posterior cingulate (PC) and parietal, temporal, and
frontal cortices (Alexander et al., 2002; Fox et al., 2000; Minoshima
et al., 1997; Thal et al., 2006), with the PC and precuneus demon-
strating the earliest metabolic deﬁcits in AD (Minoshima et al.,
1997; Reiman et al., 2004). Such deﬁcits may be associated with
metabolic dysfunctions in neurons or glial cells (Mark et al., 1997;
Piert et al., 1996), reductions in the density or activity of terminal
neuronal ﬁelds or perisynaptic glial cells (Magistretti and Pellerin,
1996; Schwartz et al., 1979), or a combination of both, and addi-
tionally highlights a metabolic role of the PC in AD.
In previous work, we identiﬁed widespread downregulated
expression of electron transport and mitochondrial translocase
genes in non-tangle bearing neurons microdissected from the PC
of AD subjects (Liang et al., 2008a, 2008b). In a separate study,
decreased cytochrome c oxidase activity was also identiﬁed across
all 6 layers of the PC cortex in AD subjects (Valla et al., 2001).
Although these ﬁndings provide evidence that mitochondrialnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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it is unclear as to what pathogenic contributions may be derived
from astrocytes in the PC. Importantly, previous studies have
shown that astrocytes demonstrate changes with respect to aging
and AD. Examples include the occurrence of structural changes in
astrocytes in the dentate gyrus of aged rats (Geinisman et al.,
1978), distinct clustering of astrocytes and astroglial hypertro-
phy in the hippocampi of aged rats (Landﬁeld et al., 1977), release
of proinﬂammatory factors from astrocytes in AD (Akiyama et al.,
2000), and buildup of beta amyloid (Ab) molecules within astro-
cytes (Akiyama et al., 2000), which may result from deﬁcits in the
ability of the cell to degrade Ab, and recent work suggesting that
activation of glial cells may have a primary role in impacting the
health of neurons in AD (Perez-Nievas et al., 2013). Given this
previous research and astrocytes’ roles in energy storage and
metabolism (Pellerin and Magistretti, 1994; Tsacopoulos and
Magistretti, 1996), immunity (Jensen et al., 2013), and the
greater than 2-fold increase in the number of astrocytes compared
with neurons in the human brain (Jensen et al., 2013; Nedergaard
et al., 2003; Sherwood et al., 2006; Sofroniew and Vinters, 2010),
we hypothesized that PC astrocytes demonstrate signiﬁcant
expression changes in AD. With the role of astrocytes in energy
storage and metabolism, we further hypothesize that genes
involved in mitochondrial processes are also dysregulated in AD
PC astrocytes.
A number of studies have evaluated human and murine
astrocyte transcriptomes using microarray technology (Cahoy
et al., 2008; Hawrylycz et al., 2012; Simpson et al., 2011; Yasui
et al., 2013) or focused approaches such as Northern blotting
(Pasternack et al., 1989) or real time polymerase chain reaction
(PCR) (Zhao et al., 2011). Simpson et al. (2011) expression proﬁled
glial ﬁbrillary acidic protein (GFAP) positive astrocytes micro-
dissected from the temporal cortex of elderly subjects and iden-
tiﬁed differentially expressed genes with respect to Braak stage
and apolipoprotein (APOE) ε4 carrier status. In a separate study,
cortical astrocytes were collected from young and old mice and
expression proﬁled to reveal altered expression of key genes
involved in neuronal signaling (Orre et al., 2014). In this study, we
used laser capture microdissection (LCM) to collect aldehyde de-
hydrogenase 1 family, member L1- (ALDH1L1) positive astrocytes
from PC cortex in both AD subjects (n ¼ 10) and healthy elderly
controls (n ¼ 10). GFAP was not used in our study because of a
number of caveats with this marker including: (Minoshima et al.,
1997) GFAP demonstrates varying levels of expression across
different cell types and regions (Roelofs et al., 2005; Sofroniew,
2009; Sofroniew and Vinters, 2010), is expressed in other glial
cells outside of astrocytes (Sofroniew and Vinters, 2010), is highly
expressed in reactive astrocytes (Eng et al., 2000; Pekny and
Pekna, 2004; Pekny et al., 1995; Sofroniew and Vinters, 2010),
and is often not identiﬁable in healthy tissue (Sofroniew and
Vinters, 2010). However, ALDH1L1 is more speciﬁc to astrocytes
than GFAP, does not preferentially mark reactive astrocytes, is
expressed in mature astrocytes, and demonstrates a wider pattern
of expression compared with GFAP such that GFAP-positive cells
make up a subset of ALDH1L1-positive cells (Eng et al., 2000;
Pekny and Pekna, 2004; Pekny et al., 1995; Sofroniew and
Vinters, 2010). It is also important to note that our previous
analysis of PC neurons was limited by the use of microarrays that
used predeﬁned probes to target only nuclear-encoded, and not
mitochondrially-encoded, genes. However, in our study here, we
capitalize on current genomic technologies to perform an unbi-
ased evaluation of all transcripts present in each sample and to
take advantage of the increased analytical sensitivity and wide
dynamic range associated with next generation sequencing. We
thus performed next generation RNA sequencing (RNAseq) ofastrocyte total RNA and describe here the ﬁrst reported
sequencing data set of PC astrocytes in AD.
2. Methods
2.1. Sample acquisition
Postmortem brain samples were collected at the Banner Sun
Health Research Institute’s Brain and Body Donation Program
from 10 clinically classiﬁed late-onset AD subjects (4 males and 6
females; 5 APOEε3/4 subjects and 5 APOEε4/4 subjects) with a
mean age at death of 83.9 years and 10 no disease (ND) healthy
elderly control subjects (6 males and 4 females; 5 APOEε3/4 sub-
jects and 5 APOEε4/4 subjects) with a mean age of death of 85.1
years. Clinically conﬁrmed AD subjects had Braak stages ranging
from IV to VI (Braak and Braak, 1991) and neuritic plaque densities
of frequent (McKhann et al., 1984). Control subjects had Braak
stages ranging from I to IV, plaque densities ranging from zero to
moderate, and were clinically conﬁrmed to not demonstrate de-
mentia. Samples were collected with a mean postmortem interval
(PMI) of 2.42 hours from the PC cortex (Brodmann areas 23 and
31). Following dissection, samples were ﬂash frozen, sectioned
(10 mm), andmounted on glass or PEN membrane slides (Carl Zeiss
Microscopy; Thornwood, NY). Information for each subject is
shown in Table 1. Total RNAwas isolated from a single section from
each subject using the Qiagen RNeasy kit to evaluate RNA integ-
rity. Samples demonstrated Agilent Bioanalyzer RNA Integrity
Number (RINs) between 7.4 and 9.4 such that all samples were
used for downstream analyses.
2.2. Staining and laser capture microdissection
PC brain sections were rapidly stained with Alexa Fluor 350
conjugated ALDH1L1 (anti-Aldehyde Dehydrogenase 1 Family,
Member L1) rabbit polyclonal antibody (ABIN882166; antibodies-
online; Atlanta, GA) to identify astrocytes. For each section, anti-
body was diluted 1:100 in phosphate-buffered saline (PBS) with
ProtectRNA RNase inhibitor (Sigma-Aldrich; St. Louis, MO). For
staining, each section was ﬁrst ﬁxed in ice-cold acetone for 3 mi-
nutes, washed 3X with PBS with RNase inhibitor, and diluted
ALDH1L1 antibody was applied and incubated in the dark on ice
for 10 minutes. The section was then washed 3X with PBS with
RNase inhibitor, followed by consecutive washes with molecular
water, 70% ethanol, 95% ethanol, and 100% ethanol. The section
was then allowed to dry at room temperature. For each subject,
approximately 300 astrocytes were LCMed from PC cortex onto
the caps of AdhesiveCap opaque tubes (Carl Zeiss Microscopy)
using the PALM LCM System (Carl Zeiss Microscopy; Thornwood,
NY). Examples of ALDH1L1þ astrocytes, as well as a pre- and post-
LCMed astrocyte, are shown in Supplementary Fig 1. Extraction
buffer (10 mL) from the Arcturus PicoPure RNA Isolation Kit (Life
Technologies; Grand Island, NY) was pipetted directly onto the cap
and incubated at 42 C for 30 minutes to create cell lysate. Lysates
were collected by centrifugation at 800xg for 2 minutes and stored
at 80 C until all samples were microdissected.
2.3. RNA isolation
Total RNA was isolated from all cell lysates using the Arcturus
PicoPure RNA Isolation Kit (Life Technologies; Grand Island, NY)
following the manufacturer’s protocol. DNase treatment was
additionally performed during RNA isolation using the RNase-free
DNase set (Qiagen; Valencia, CA) following Appendix A of the
Arcturus PicoPure manufacturer’s protocol.
Table 1
Subject information
Sample Gender APOE PMI (h) Expired
age (y)
Plaque density Braak
score
NIA-R
Control 1 M 3/3 3.25 80 Sparse II Criteria not met
Control 2 F 3/3 2.25 82 Zero II Criteria not met
Control 3 F 3/3 2.50 95 Zero III Criteria not met
Control 4 M 3/3 2.66 78 Zero II Criteria not met
Control 5 F 3/4 1.50 85 Moderate III Criteria not met
Control 6 M 3/4 2.00 91 Zero IV Criteria not met
Control 7 M 3/4 2.33 76 Sparse I Criteria not met
Control 8 F 3/4 2.50 85 Zero III Criteria not met
Control 9 M 3/3 3.00 82 Zero IV Criteria not met
Control 10 M 3/4 1.87 97 Zero III Criteria not met
AD 1 F 3/3 1.50 85 Frequent VI High
AD 2 M 3/3 2.95 82 Frequent V High
AD 3 F 3/3 2.15 84 Frequent V High
AD 4 M 3/4 2.25 78 Frequent VI High
AD 5 F 3/4 2.16 78 Frequent VI High
AD 6 F 3/4 2.66 85 Frequent V High
AD 7 F 3/4 2.70 89 Frequent VI High
AD 8 M 3/4 3.92 79 Frequent V High
AD 9 M 3/3 2.05 86 Frequent VI High
AD 10 F 3/3 2.15 93 Frequent IV Intermediate
Key: AD, Alzheimer’s disease; APOE, apolipoprotein; F, female; M, male; NIA-R, National Institute on Aging and Reagan Institute neuropathologic AD severity score; PMI,
postmortem interval.
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All isolated total RNA from each LCM collection was used to
generate and linearly amplify cDNA using the Ovation RNAseq
System v2 (Nugen; San Carlos, CA) following the manufacturer’s
protocol. This system uses a primer mix to initiate ampliﬁcation
from the 30 end of genes as well as throughout the entire tran-
scriptome. Ampliﬁed cDNA was input into the TruSeq DNA Sample
Preparation Kit v2 (Illumina; San Diego, CA) and sequencing li-
braries were generated following the manufacturer’s protocol with
the exception that 10 cycles of PCR was used for library enrichment.
Final libraries were analyzed on a Bioanalyzer DNA 1000 chip
(Agilent Technologies; Santa Clara, CA). Equimolar pools of libraries
were created for sequencing and reassessed on the Bioanalyzer
before sequencing.2.5. Paired-end sequencing
Library pools were clustered onto Illumina v3 ﬂowcells using the
Illumina Truseq PE Cluster Kit v3 on the Illumina cBot. Clustered
ﬂowcells were sequenced by synthesis on the Illumina HiSeq2000
using Illumina’s Truseq PE Cluster Kit v3 and Illumina’s TruSeq SBS
Kits v3 for paired 83 base pair read lengths.2.6. Sequencing data analysis
Raw sequencing data in the form of BCL ﬁles were converted to
FASTQ ﬁles using Illumina BCLConverter software. Datawere aligned
against the human reference genome (build 37) using TopHat1.2
(Trapnell et al., 2009, 2012) and Cufﬂinks (Trapnell et al., 2012) was
used to assemble aligned reads into transcripts. HTSeq (http://
www-huber.embl.de/users/anders/HTSeq/doc/overview.html) was
used to generate a counts table from Cufﬂinks output and DESeq2
v1.4.0 (Anders and Huber, 2010) (http://www.bioconductor.org/
packages/devel/bioc/html/DESeq2.html) was used to calculate
normalized read counts for each gene and/or transcript and to
perform expression analysis. To evaluate inter-sample variability, we
performed Pearson correlation analyses in R using normalized
counts across all samples to identify any outliers.DESeq2 uses a generalized linear model to evaluate differential
expressionwhile accounting for biological variance and uses aWald
test statistic to evaluate signiﬁcance. A DESeqDataSet object is
created using HTSeq counts and the DESeq wrapper function is
called to perform differential analyses. The fold change is deter-
mined by dividing the average normalized read counts of AD
samples over control samples for each transcript. Independent
ﬁltering and Cook cutoff parameters were set to ON to remove
outliers and genes with low normalized read counts. p-values were
corrected using the Benjamini and Hochberg False Discovery Rate,
and results were annotated using the Biomart online portal (http://
www.ensembl.org/biomart/martview).
MetaCore from Thompson Reuters (v6.10 build 40,284) was
used for GeneGo pathway analysis. Weighted gene co-expression
network analysis (WGCNA) (Horvath et al., 2006; Zhang and
Horvath, 2005) was performed on differentially expressed genes
(corrected p < 0.05). Gene sets were loaded into the WGCNA R
package, and annotation of generated modules was performed
using DAVID (Dennis et al., 2003).
All data generated through this study are accessible through
National Center for Biotechnology Information (NCBI) database of
genotypes and phenotypes (dbGaP; accession phs000745.v1.p1).2.7. Quantitative-polymerase chain reaction validation
Quantitative-polymerase chain reaction (qPCR) was performed
to experimentally validate differentially expressed transcripts in 2
phases: ﬁrst, qPCR was performed on total RNA from astrocytes
microdissected from 3 control subjects and 3 AD subjects and
second, across total RNA isolated fromwhole PC sections from all 20
sequenced subjects (during initial sample quality control analyses
described in Section 2.1). For the ﬁrst phase, validation was per-
formed on cDNA synthesized and linearly ampliﬁed from LCMed
astrocyte pools using the Nugen Ovation RNA-Seq System V2 kit.
Additional remaining cDNA from original collections used for
sequencing were used for validations for AD4, AD6, and ND9. Based
on sample availability, newly microdissected astrocyte pools were
collected for AD8, ND1, and ND2. Total RNA was isolated using the
PicoPure RNA Isolation kit and was used to generate cDNA for
validation using the Nugen Ovation RNA-Seq System V2 kit.
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was selected as a reference gene because it demonstrated consis-
tent high expression (greater than 1000 normalized read counts in
each of all 20 samples) in RNAseq data and also demonstrated the
lowest variance across all 20 samples. For the second phase,
remaining total RNA from initial sample quality control analysesN
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performed in 10 mL reactions using QuantiFast SYBR Green RT-PCR
kit (Hilden, Germany) per the manufacturer’s instructions on the
Roche Lightcycler 480 system (Basel, Switzerland), with the
exception that the initial reverse transcription step was omitted.
Reactions were performed in triplicate with 1 nontemplate control.
3. Result and discussion
3.1. RNA sequencing
We sequenced 10 AD PC astrocyte pools and 10 ND (control) PC
astrocyte pools to generate over 5.22 billion total reads and over
295 Gb of Q30 sequencing data. Both AD and ND groups were
controlled for APOE genotype. An average of 123,214,013 mapped
reads were sequenced per sample. Pearson correlation analyses on
normalized read counts across all samples resulted in r values all
greater than 0.88. All samples were thus included for differential
expression analyses.
3.2. Differentially expressed genes in AD PC astrocytes
Comparison of AD samples with controls led to the
identiﬁcation of 226 differentially expressed genes (corrected
p < 0.05; Supplementary Table 1). Genes demonstrating the
greatest log2-fold changes are shown in Fig. 1. A total of
55.8% of signiﬁcant genes demonstrated up regulated
expression.
Differentially expressed genes include mitochondrial genes,
deﬁned as mitochondrially encoded genes or MitoCarta genes
(Pagliarini et al., 2008) (Table 2). These genes include Fas-activated
serine/threonine phosphoprotein kinase domains 2(FASTKD2;
log2 ratio ¼ 3.50), tRNA methyltransferase 61 homolog B
(TRMT61B; log2 ratio ¼ 2.81), pitrilysin metalloproteinase 1
antisense RNA 1 (PREP/MP1; PITRM1-AS1; log2 ratio ¼ 3.20),
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like
2(NDUFA4L2; log2 ratio ¼ 3.23), and mitochondrially encoded
NADH dehydrogenase 1 pseudogene 22(MTND1P22; log2 ratio ¼
6.71). FASTKD2, which localizes to the mitochondrial matrix, has
been predicted to be involved in regulating apoptosis in breast
cancer such that knockdown of the gene resulted in inhibition of
apoptosis (Yeung et al., 2011). Homozygous nonsense mutations in
FASTKD2 have also been previously reported in mitochondrial
encephalomyopathy, a condition associated with decreased cyto-
chrome c oxidase activity (Ghezzi et al., 2008). Decreased
expression of FASTKD2 in AD PC astrocytes thus suggests pertur-
bation of apoptosis regulation in these cells. TRMT61B, which also
localizes to mitochondria, methylates adenosine at position 58 of
cytoplasmic mitochondrial transport RNAs (tRNAs) and is hy-
pothesized to improve processing, stability, or function of tRNAsTable 2
Differentially expressed MitoCarta genes in AD PC astrocytes (corrected p < 0.05)
Ensembl ID Gene name Description
ENSG00000118246 FASTKD2 FAST kinase domains 2
ENSG00000237399 PITRM1-AS1 PITRM1 antisense RNA 1
ENSG00000065911 MTHFD2 Methylenetetrahydrofolate dehydrogen
(NADPþ dependent) 2, methenyltetrahy
ENSG00000171103 TRMT61 B tRNA methyltransferase 61 homolog B (
ENSG00000168394 TAP1 Transporter 1, ATP-binding cassette, sub
ENSG00000122140 MRPS2 Mitochondrial ribosomal protein S2
ENSG00000047230 CTPS2 CTP synthase 2
ENSG00000185633 NDUFA4L2 NADH dehydrogenase (ubiquinone) 1 a
ENSG00000251407 MTND1P22 MT-ND1 pseudogene 22 (unprocessed)
Key: AD, Alzheimer’s disease; PC, posterior cingulate; tRNA, transfer RNA.required for translation of respiratory factors (Chujo and Suzuki,
2012).
PITRM1/PREP/MP1 encodes an enzyme that is localized to the
mitochondrial matrix (Chow et al., 2009) and that has been shown
to degrade Ab (Falkevall et al., 2006). Activity of this enzyme has
also been reported to be decreased in the temporal lobe of AD
subjects and transgenic AD murine brains (Alikhani et al., 2011).
Decreased expression of a transcript antisense to PITRM1 may be
associated with changes in regulation of PITRM1 expression.
NDUFA4L2 has been reported to inhibit activity of complex I under
hypoxic conditions through hypoxia-inducible transcription
factor-1 (HIF-1) (Tello et al., 2011) such that its increased expres-
sion in AD PC astrocytes may impact complex I activity. Finally, we
identiﬁed altered expression of a mitochondrially encoded pseu-
dogene, MTND1P22. Pseudogenes, represented by DNA sequences
that are similar to protein-coding genes but do not generate
functional proteins, have historically been assumed to be
nonfunctional but more recent research suggests that pseudogene
transcripts may represent regulatory long noncoding RNAs
(Poliseno, 2012). The differentially expressed mitochondrial
pseudogene identiﬁed here is an unprocessed pseudogene,
resulting from gene duplication, whereas processed pseudogenes
result from a retrotransposition event (Poliseno, 2012). To date,
there have been no reports of biological evidence of mitochond-
rially encoded pseudogenes, although nuclear-encoded mito-
chondrial pseudogenes are known (Woischnik and Moraes, 2002).
Our understanding of these pseudogenes remains limited. How-
ever, given our current understanding of pseudogenes and the
sequence similarity of this transcript with the NADH dehydroge-
nase 1 gene, MTND1P22 may have a role in transcription regula-
tion. Additional differentially expressed mitochondrial genes
include CTP synthase 2 (CTPS2; log2 ratio ¼ 3.15), mitochondrial
ribosomal protein S2 (MRPS2; log2 ratio ¼ 2.88), methylenete-
trahydrofolate dehydrogenase (NADPþ dependent) 2, meth-
enyltetrahydrofolate cyclohydrolase (MTHFD2; log2 ratio¼3.18),
and transporter 1, ATP-binding cassette, subfamily B (TAP1; log2
ratio ¼ 2.83).
Pathway analysis of differentially expressed genes revealed that
the most signiﬁcantly impacted pathway in AD PC astrocytes is
immune system response (Table 3) with 82.4% of signiﬁcant genes
in this pathway demonstrating upregulated expression in AD PC
astrocytes. Furthermore, WGCNA, which performs functional or-
ganization of genes based on coexpression, on differentially
expressed genes in AD astrocytes generated 7 coexpression mod-
ules, whereby the largest module (Fig. 2A; turquoise module)
demonstrated the highest DAVID enrichment scores for immune
response and immune processes, including antigen processing and
presentation and lymphocyte activation. Genes in each module are
shown in Fig. 2B. Given the role of astrocytes in central nervous
system immunity under circumstances when insults are presentLog2-fold p Corrected p
3.67 6.41  108 1.37  103
3.61 4.67  104 4.78  102
ase
drofolate cyclohydrolase
3.18 2.95  104 3.93  102
Saccharomyces cerevisiae) 3.01 3.19  104 4.09  102
family B (MDR/TAP) 2.83 3.51  104 4.25  102
2.88 6.84  105 2.40  102
3.15 9.63  105 2.65  102
lpha subcomplex, 4-like 2 3.23 3.23  104 4.09  102
6.71 5.14  106 6.48  103
Table 3
Pathway analysis of differentially expressed genes identiﬁed in AD PC astrocytes (corrected p < 0.05)
# Pathway/process p Radio Down (%) Up (%) Genes
1 Immune system response 4.21  105 21/970 17.6 82.4 ARHGEF11, C3, CD74, CD81, CD93, CDKN1A,
CLU, CYBB, FCGR2A, GSN, HLA-DRB1, IL13RA1,
ISG15, PLA2G4A, PSMD4, TAP1, TNS1
2 Hematopoiesis 3.10  102 6/270 20.0 80.0 CDKN1A, CYBB, FTL, TAP1, TPO
3 Transcription regulation 1.48  101 1/18 0.0 100.0 TBP
4 Vasoconstriction 2.95  101 4/311 75.0 25.0 ARHGEF11, OCLN, PHKG1, PLA2G4A
5 Calcium signaling 3.31  101 5/430 50.0 50.0 CDKN1A, HLA-DRB1, IL13RA1, P2RY6, PHKG1, PLA2G4A
6 Oxidative stress regulation 4.04  101 6/578 14.3 85.7 CYBB, FTL, HSF1, IL13RA1, PLA2G4A, RPS4X, SEPP1
7 Blood clotting 4.48  101 3/278 33.3 66.7 FCGR2A, PLA2G4A, VKORC1
8 Tissue remodeling and wound repair 4.98  101 5/524 40.0 60.0 CDKN1A, LRP5, OCLN, PLA2G4A, TGFA
9 Inﬂammatory response 5.55  101 6/673 25.0 75.0 CYBB, IL13RA1, PLA2G4A, TNS1
10 Mitogenic signaling 5.59  101 5/560 20.0 80.0 CDKN1A, IGFBP5, IL13RA1, PLA2G4A, TGFA
11 Obesity 5.64  101 2/212 0.0 100.0 CDKN1A, TNS1
12 Myogenesis regulation 5.72  101 1/95 0.0 100.0 CDKN1A
13 Vasodilation 5.79  101 3/337 66.7 33.3 ARHGEF11, FOSB, PHKG1
14 Vitamin and cofactor
metabolism and its regulation
5.91  101 6/697 33.3 66.7 ENPP3, FTL, MTHFD2, PHPT1, SCARB1, VKORC1
15 Lipid biosynthesis and regulation 6.43  101 3/370 100.0 0.0 PLA2G4A
16 Cystic ﬁbrosis disease 6.75  101 5/636 14.3 85.7 ANXA2, CYBB, FOSB, PSMD4, RAE8A, TAP1, TGFA
17 Vascular development (angiogenesis) 6.89  101 4/522 25.0 75.0 CDKN1A, MKNK2, PLA2G4A, VHL
18 Protein degradation 6.94  101 2/269 0.0 100.0 CDKN1A, HSF1
19 Nucleotide metabolism
and its regulation
6.97  101 3/401 33.3 66.7 CTPS2, ENPP3, GMPR
20 Cell differentiation 7.25  101 7/922 57.1 42.9 CDKN1A, FOSB, IL13RA1, NOTCH3, OCLN, PHKG1, PLA2G4A
Key: AD, Alzheimer’s disease; PC, posterior cingulate.
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processes are the most heavily perturbed pathways in AD PC
astrocytes correlates with known astrocyte functions. These
changes may be associated with activation of astrocytes in response
to one or all the following: the presence of beta-amyloid, weak-
ening of the blood-brain barrier (BBB), and exposure of sequenced
cells to inﬂammatory cytokines.
Differentially expressed immune system response genes
include clusterin (CLU), apolipoprotein J (APOJ) (log2 ratio ¼
1.97), complement component 3 (C3; log2 ratio ¼ 2.82), and
cluster of differentiation 74 molecule, major histocompatibility
complex, class II invariant chain (CD74; log2 ratio ¼ 3.52). Two
large genome-wide association studies that evaluated over
23,000 individuals implicated an SNP, rs11136000, in CLU that is
associated with late-onset AD (Harold et al., 2009; Lambert
et al., 2009). CLU encodes a heterodimeric chaperone that has
been found to inhibit Ab oligomer uptake in human astrocytes
(Mulder et al., 2014) such that increased expression of this gene
in AD PC astrocytes may affect Ab clearance. C3 encodes a
member of the complement system, and this gene has been
reported to demonstrate an age-related increase in expression
in control (C57BL/6) mice with more signiﬁcant increases in
transgenic amyloid precursor protein (APP) mice during for-
mation of Ab (Reichwald et al., 2009). Finally, we identiﬁed
upregulated expression of CD74 in AD PC astrocytes. CD74,
which is involved in antigen presentation to T cells during an
immune response, has also been found to interact with Ab and
obstruct Ab production in HeLa cells (Matsuda et al., 2009).
Upregulated expression of CD74 in AD PC astrocytes may thus
represent an effect resulting from multiple causes encompass-
ing both immune system and Ab responses. Notably, the im-
mune system response genes described here have all been
shown to be associated with APP/Ab such that APP/Ab may be a
key initiating factor in immune response pathways. Of rele-
vance, the proximity of LCMed astrocytes to Ab plaques was not
evaluated during microdissection, but the ﬁndings reported
here may be inﬂuenced by the higher plaque load in the AD
subjects.3.3. Experimental validation of differentially expressed genes
Based on sample availability, qPCR experiments were performed
to validate expression changes. qPCR was ﬁrst performed across 3
control and 3 AD subjects using cDNA generated from total RNA
isolated from microdissected PC astrocytes to validate gene
expression changes of 7 selected differentially expressed genes, or
transcripts, identiﬁed through the AD versus ND comparison
(Supplementary Fig. 2A and B). These genes and/or transcripts
include RP11-488L18.10, RP11-797H7.1, TRMT61B, PPP5C, C3, TBP, and
CLU. Because of limited availability of these samples, we also per-
formed qPCR validation on total RNA that was isolated from an
entire PC section from each subject during initial sample quality
control analyses (n ¼ 20; Supplementary Fig. 2A and C). These
analyses were performed on 6 selected differentially expressed
genes including TRMT61B, CTPS2, NDUF4AL2, CD74, CLU, and C3.
Overall, the directionality of expression changes was validated
across all genes. Notably, CLU and C3, both of which were evaluated
by qPCR in microdissected astrocytes and whole PC sections,
demonstrated larger increases in the astrocyte-speciﬁc data and
lower increases in whole PC sections to show that the astrocyte-
speciﬁc signal is diluted in whole PC sections.
4. Conclusions
In this study, we identiﬁed altered expression of mitochondrial
and immune system response genes in PC astrocytes in the context
of AD. Based on WGCNA and pathway analyses, immune response
processes appear to be most heavily impacted in PC astrocytes in
AD subjects. These results provide evidence that brain immunity
and mitochondrial functions in PC astrocytes are perturbed in AD.
Given the role of astrocytes as immune sensors in the brain
(Jensen et al., 2013), these cells may represent a ﬁrst line of defense
in response to insults, which may include inﬂammation, injury, or
infection. Differentially expressed immune response genes in AD
subjects include numerous genes that have been previously
implicated as having key roles associated with Ab production and
clearance. However, it remains to be clariﬁed if alterations in
AB
Fig. 2. WGCNA dendrogram of differentially expressed genes in AD PC astrocytes. A total of 226 differentially expressed genes (corrected p < 0.05) were used for WGCNA. (A) Seven
coexpression modules were generated, and the total genes for each module are as follows: blue ¼ 26, brown ¼ 22, green ¼ 14, gray ¼ 53, red ¼ 12, turquoise ¼ 83, and yellow ¼ 16.
Each open-ended arm in the dendrogram represents a separate gene. (B) Genes falling within each module are listed. Abbreviations: AD, Alzheimer’s disease; PC, posterior
cingulate; WGCNA, Weighted gene coexpression network analysis.
S. Sekar et al. / Neurobiology of Aging 36 (2015) 583e591 589immunity pathways parallel, overlap, or potentially precede, Ab
formation. Deeper investigations into young pre-AD and MCI (mild
cognitive impairment) subjects will be needed to determine if im-
mune response processes are similarly affected before onset of AD,
and if perturbation of immune response pathways coincides with
CMRgI deﬁcits seen in young APOEε4 carriers. Likewise, additional
regional analyses are needed to evaluate if immune response
pathways are also heavily impacted in brain regions differentially
affected by AD.
Although this study lends new insight into astrocytic changes in
AD, we are limited by a few caveats. Although microdissection was
used to collect astrocytes for sequencing, it is possible that frag-
ments of adjacent endothelial cells or neurons may have also been
collected. To mitigate this possibility, astrocytes were individually
collected, but it is possible that astrocytic end feet may have been
missed. As a secondary conﬁrmation, we evaluated GFAP expres-
sion and identiﬁed increased expression in AD subjects (uncorrec-
ted p ¼ 1.63  103, log2 fold ¼ 2.49), as expected because of
upregulation of GFAP in reactive astrocytes in AD (Eng et al., 2000;
Panter et al., 1985; Sofroniew and Vinters, 2010), although we did
not speciﬁcally collect GFAP-positive cells. Another limitation isthat we do not know the mitochondrial content of the micro-
dissected cells, whereby differential expression of mitochondrial
genes may reﬂect differential mitochondrial loads. Differences in
mitochondrial content in both astrocytes and neurons in the
context of AD have yet to be investigated. Third, it is not known if
increased expression of mitochondrial genes directly translates to
activation of energy metabolism pathways.
This study is also prefaced by signiﬁcant region-speciﬁc
transcriptional analyses in AD that have demonstrated discrete al-
terations in different areas of the brain. Key upregulated and
downregulated genes have been identiﬁed in the amygdala and
cingulate cortex of postmortem AD brains, correlating to processes
including inﬂammation and energy metabolism, respectively
(Loring et al., 2001). Although analyses were performed on whole
tissue, upregulation of inﬂammation genes and downregulation of
energy metabolism genes parallel our ﬁndings here, in addition to
our previous report of decreased expression of electron transport
genes in PC neurons (Liang et al., 2008a, 2008b). In a separate study,
microarray analysis of LCMed CA1 hippocampal gray matter from
formalin ﬁxed parafﬁn embedded (FFPE) sections of AD brains
suggests that increased expression of glial transcription factors
S. Sekar et al. / Neurobiology of Aging 36 (2015) 583e591590genes, among others, may be concentrated in white, and not gray,
matter (Blalock et al., 2011). Although transcriptional analysis of
FFPE samples may be associated with decreased speciﬁcity, this
study provides evidence of divergent expression changes also at the
level of gray and white matter. In neuron-speciﬁc transcriptomic
studies in AD, key expression alterations were also identiﬁed across
multiple brain regions, including the PC, hippocampal CA1, and
middle temporal gyrus, in cortical neurons (Liang et al., 2008a,
2008b, 2010).
Such ﬁndings emphasize the need to consider cell-speciﬁc re-
sponses, roles, and contributions to AD pathogenesis. The beneﬁts
of RNAseq support our ability to perform cell-speciﬁc analyses by
widening the dynamic range for transcript detection and by sup-
porting an unbiased evaluation of all transcripts in a sample.
Furthermore, identiﬁcation of differentially expressed mitochon-
drial and immune response genes, and the respective roles of these
genes in Ab generation and clearance, lends valuable insight into
previously uncharacterized cells in the PC. As we continue to
improve our understanding of the discrete molecular events that
occur in the PC in AD, we will strengthen our ability to identify
potential targets for slowing and arresting disease progression at
earlier stages of AD.
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